抗生素耐药性 1008条(本栏目收费,不能显示细节,电话13136136841)
toxin‐antitoxin modules 189–191 191
antibiotic sensitivity testing 536 536
antibiotics (bacteriocins) natural and synthetic molecules 194–195 195
antibiotics,repurposing antibiotic‐adjuvant combination approach 456 456
antibiotic‐antibiotic combination approach 455–456 456
anti‐virulence strategy 454 454
aspergillomarasmine A 458 458
β‐lactam and β‐lactamase inhibitor combination 456–457 457
combination therapy 454–455 455
imipenem‐cilastatin/relebactam triple combination 457–458 458
intrinsic resistance challenges and strategies 458–461 461
as potent agents against MDR GNB 467–468 468
with high molecular weight by enhancing outer membrane permeability 461–464 464
with large molecular weight and other antibacterials as antipseudomonal agents 464–467 467
antibiotic with non‐antibiotic adjuvants,pairing of 485–488 488
antibodies bezlotoxumab vs. Clostridium difficile 479 479
LC10 vs. Staphylococcus aureus 480–481 481
panobacumab vs. Pseudomonas aeruginosa 479–480 480
plus clavanin 482–483 483
raxibacumab vs. Bacillus anthracis 478–479 479
antibody‐antibiotic conjugate 415–416 416
antifungal polyene macrolides 100 100
antimicrobial peptides (AMPs) 279,297–298 298
anti‐biofilm activity 507 507
application of phage to treat bacteria 491 491